Mabel Ryder on Tumor-Associated Macrophages in Thyroid Cancer

Article

Mabel Ryder, MD, endocrinologist and medical oncologist, Mayo Clinic, discusses targeting the tumor microenvironment in thyroid cancer. 

Mabel Ryder, MD, endocrinologist and medical oncologist, Mayo Clinic, discusses targeting the tumor microenvironment in thyroid cancer. 

Previously, most research thyroid cancer progression has been done on the cancer cell itself, Ryder says. In her research, Ryder looked at how cells in the microenvironment would affect thyroid cancer cells and promote progression.

Using mouse models, Ryder identified tumor-associated macrophages and found evidence that the cells promote thyroid cancer progression. 

Ryder says that tumor-associated macrophages represent a potential therapeutic target for advanced thyroid cancer, particularly in patients whose disease has been resistant to most molecular targeted therapies.  

Related Videos
Meaghan Mooney, B.S.N., RN, OCN, during the Extraordinary Healer interview
Colleen O’Leary, DNP, RN, AOCNS, EBP-C, LSSYB, in an interview with Oncology Nursing News.
Michelle H. Johann, DNP, RN, PHN, CPAN, WTA, in an interview with Oncology Nursing News explaining surgical path cards
Alison Tray, of Hartford Healthcare, discusses her team's research on a multidisciplinary team approach to manage the cancer drug shortage
Related Content
© 2024 MJH Life Sciences

All rights reserved.